MLH1 and MSH2 variants account for most LS cases, with MLH1 pathogenic/likely pathogenic (P/LP) variants primarily associated with colorectal tumors, whereas MSH2 P/LP variants are linked to an increased risk of colorectal, endometrial, and ovarian cancers (2). This evidence concerns the gene MSH2 and ovarian cancer.